Search hospitals > Massachusetts > Boston
Dana Farber Cancer Institute
Claim this profileBoston, Massachusetts 02215
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Solid Tumors
Conducts research for Parotid Gland Cancer
3428 reported clinical trials
268 medical researchers
Summary
Dana Farber Cancer Institute is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Adult T-Cell Leukemia/Lymphoma, Solid Tumors, Parotid Gland Cancer and other specialties. Dana Farber Cancer Institute is involved with conducting 3,428 clinical trials across 1,467 conditions. There are 268 research doctors associated with this hospital, such as Susan Chi, MD, Geoffrey I. Shapiro, Haeseong Park, MD, and Ryan Sullivan, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Susan Chi, MDDana-Farber Cancer Institute5 years of reported clinical research
Expert in Brain Tumor
Expert in Diffuse Intrinsic Pontine Glioma
29 reported clinical trials
62 drugs studied
Geoffrey I. ShapiroDana-Farber Cancer Institute8 years of reported clinical research
Expert in Cancer
Expert in Solid Tumors
27 reported clinical trials
57 drugs studied
Haeseong Park, MDWashington University School of Medicine6 years of reported clinical research
Studies Cervical Adenocarcinoma
Studies Cancer
27 reported clinical trials
55 drugs studied
Ryan Sullivan, MDMassachusetts General Hospital3 years of reported clinical research
Expert in Melanoma
Expert in Solid Tumors
22 reported clinical trials
35 drugs studied
Clinical Trials running at Dana Farber Cancer Institute
Breast Cancer
Ovarian Cancer
Multiple Myeloma
Lung Cancer
Lymphoma
Chronic Lymphocytic Leukemia
Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Melanoma
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Avelumab + Palbociclib/Hydroxychloroquine
for Breast Cancer
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Recruiting3 awards Phase 212 criteria
CDK4/6 Inhibitors
for Metastatic Breast Cancer
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing).
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dana Farber Cancer Institute?
Where is Dana Farber Cancer Institute located?
Who should I call to ask about financial aid or insurance network?
What insurance does Dana Farber Cancer Institute accept?
What awards or recognition has Dana Farber Cancer Institute received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.